Editas Medicine Inc. (NASDAQ:EDIT) saw an uptick in trading volume on Wednesday . 364,004 shares were traded during trading, an increase of 158% from the previous session’s volume of 141,092 shares.The stock last traded at $22.11 and had previously closed at $23.28.

A number of brokerages have recently issued reports on EDIT. Jefferies Group upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Wednesday. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Tuesday, July 19th. Cowen and Company reiterated a “buy” rating on shares of Editas Medicine in a research report on Monday, May 16th. Finally, Vetr upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 target price on the stock in a research report on Monday, May 9th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $33.50.

The firm’s market cap is $756.89 million. The stock’s 50-day moving average price is $25.60 and its 200 day moving average price is $29.84.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.54) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.54). Equities research analysts expect that Editas Medicine Inc. will post ($2.35) earnings per share for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.